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Abstract
Background: Co-infection with HIV negatively impacts the progression of chronic hepatitis B virus (HBV) infection,
including causing rapid progression to liver fibrosis. Sub-Saharan Africa represents arguably the most important
intersection of high endemicity of both chronic hepatitis B virus (HBV) infection and HIV infection.
Methods: We recruited 46 HBV/HIV-co-infected; 47 HBV-monoinfected; 39 HIV-monoinfected; and 37 HBV/HIV-uninfected
patients from Tygerberg Hospital, Cape Town, South Africa. All HIV-infected patients were on antiretroviral therapy for
≥3 months. Liver stiffness measurements were assessed using the Fibroscan (Fibroscan 402, Echosens). Cell-based
immunomarkers were measured by flow cytometry. Soluble serum/plasma immunomarkers were measured by
Luminex technology and enzyme immunoassays. HIV (COBAS/Ampliprep TaqMan HIV-1) and HBV viral loads (in-house
assay) were also performed.
Results: HBV/HIV co-infected patients showed significantly higher levels of immune activation %CD8+/HLA-DR+/CD38+
(median 30%, interquartile range: 17–53) and %CD8+/PD-1 (median 22%, interquartile range: 15–33), p≤ 0.01 compared
to all other study groups. Despite this, the HBV-mono-infected group had the highest proportion of patients with
advanced liver fibrosis (≥13 kPa) as measured by Fibroscan (18%). HBV mono-infected patients showed highest
expression of most cytokines including IL-17 and basic fibroblastic growth factor. There was significant positive
correlation between detectable HIV and HBV viral replication and liver fibrosis but not immune activation or gut
translocation.
Discussion: Highly-active antiretroviral therapy, including tenofovir, is effective against both HIV and HBV. Earlier
therapy in the co-infected patients may therefore have controlled viral replication leading to better fibrosis scores
when compared to HBV mono-infection in this study. On-going HBV and HIV viraemia, rather than microbial
translocation or immune activation, appear to be the drivers of liver fibrosis. Moderate to advanced liver fibrosis
in HBV-mono-infection may well indicate poor access to screening and treatment of HBV infection.
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Background
Sub-Saharan Africa represents arguably the most important
intersection of high endemicity of both chronic hepatitis B
virus (HBV) infection and HIV infection. HIV infection
has been reported to alter the natural history of HBV
by increasing HBV replication rates leading to elevated
hepatitis B viraemia, delaying seroconversion from HBeAg
to anti-HBe and also hastening the development of liver
fibrosis [1]. Findings from elsewhere have shown that
patients co-infected with HIV and HBV present with
rapidly progressive liver disease, have a higher risk of
developing cirrhosis and an elevated risk of death from
liver-related disease compared to those with either HBV
or HIV infection alone [2–5].
Chronic HBV infection is associated with immune
tolerance in the liver, particularly during the immune
tolerance phase [6]. However, HBV/HIV co-infection
may lead to the loss of immune tolerance. Acute HIV
infection results in severe depletion of gut associated
lymphoid tissue cells (primarily memory T lymphocytes),
which is associated with epithelial damage and results in
leakage of gut-derived microbial antigens into the systemic
circulation. Consequently, individuals with HIV infection
have significantly elevated systemic levels of microbial
products compared to HIV-uninfected individuals [7].
Translocated microbial products cause immune activation
and have been associated with hepatic fibrosis [8]. Increased
serum LPS levels are associated with liver fibrosis progres-
sion from various aetiologies such as chronic misuse of
alcohol and non-alcoholic steatohepatitis [9].
Within the liver environment, LPS binds to TLR-4 on
Kupffer cells and hepatocytes [10]. The interaction of LPS
with TLR-4 initiates secretion of proinflammatory and
fibrogenic cytokines [9, 11, 12]. Several pro-inflammatory
cytokines, such as IL-1β, IL-6 and IFN-γ, have been associ-
ated with chronic inflammation in the liver environment
and may be important in the relationship between inflam-
mation and hepatocarcinogenesis [13]. The expression
of these pro-inflammatory cytokines has been shown to
increase with exposure to LPS while secretion of potentially
protective anti-inflammatory cytokines such as IL-10 is
reduced [13]. We explored the association between immune
dysregulation caused by HIV infection and development of
liver fibrosis in South African patients with or without HBV
co-infection with the hypothesis that in patients with HIV/
HBV co-infection, HIV facilitates the development of liver
fibrosis via immune activation in response to the leakage of
gut microbial products into the systemic circulation.
Methods
Study participants
Ethics approval was obtained from the Health Research
Ethics Committee at Stellenbosch University. HBV/HIV
co-infected and HIV-mono-infected patients were recruited
from the Infectious Diseases Clinic while HBV-mono-
infected and HBV-/HIV-uninfected patients (controls) were
enrolled among patients attending the Gastroenterology
Clinic at Tygerberg Hospital, Cape Town following written
informed consent. Patients with other known liver diseases
or HCV infection were excluded from the study. Patients
of age < 18 years were also excluded. Epidemiological data
as well as data on alcohol consumption and history of
herbal medicine use were collected using a study-specific
questionnaire.
Non-invasive measurement of liver fibrosis and specimen
collection
Patients had liver stiffness measurements by transient
elastometry (TE) using the Fibroscan 402 (Echosens, Paris,
France). TE cut-off values of < 7 kPa, 7.0–13.0 and ≥
13 kPa were used to assign liver fibrosis severity as defined
previously [14]. Blood was drawn for platelet count, aspar-
tate transaminase (AST) and alanine transaminase (ALT)
used to calculate the AST to platelet ratio index (APRI)
and fibrosis-4 (FIB-4) scores. Aliquots of EDTA whole
blood were also prepared for flow cytometric immune cell
phenotyping.
Virological and immunological testing
Serum specimens of HBV-infected patients were tested
for HBeAg and antibodies to HBeAg (anti-HBe) using
DiaSorin ETI-EBK PLUS and ETI-AB-EBKPLUS immuno-
assay kits (DiaSorin, Saluggia, Italy). HBV DNA testing was
performed using an in-house quantitative PCR as previously
described [15]. Samples with detectable HBV DNA were se-
quenced on the polymerase region of the HBV genome.
HIV-1 viral loads were performed using the COBAS/Ampli-
prep TaqMan HIV-1 version 2.0 on the COBAS TaqMan
Analyser (Roche Molecular Systems, CA). CD4 cell counts
were performed on EDTA-anticoagulated blood using
the BD TruCount on the BD FACSCalibur instrument
(BD Biosciences, San Jose, CA).
Flow cytometric measurement of % CD8+ and CD4+ T-cells
expressing CD38, HLA-DR, PD-1 and CTLA-4
Two panels were designed; Immune Activation Panel
and Immune Exhaustion Panel. The Immune Activation
Panel consisted of the following fluorochrome-coupled
monoclonal antibodies: CD3-FITC; CD4-ECD; CD8-PC-7;
CD45-KO; CD38-PE and; HLA-DR-APC (Beckman Coulter,
MI). The Immune Exhaustion Panel was composed of CD3-
FITC; CD4-ECD; CD8-PC7; CD45-KO; CTLA-4-PE and;
PD-1-APC. Flow cytometry data acquisition was performed
using a Navios flow cytometer (Beckman Coulter). Optimal
volatges for acquisition were determined, compensation and
fluorescence minus one analyses were performed before
testing of study samples. The gating strategy is shown in
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Additional file 1: Figure S1. Data analysis was performed
using Beckman Coulter Kaluza software.
Measurement of serum markers of microbial translocation
and soluble cytokines
Plasma soluble CD14 (sCD14) and lipoprotein binding
protein (LBP) levels were measured as biomarkers of
LPS activity by enzyme immunoassays using the Human
sCD14 and the Human LBP ELISA kits (Hycult Biotech,
Uden, Netherlands). Serum cytokines and chemokines
were measured by Luminex technology using the premixed
Bio-Plex pro Human Cytokine Grp 1 panel 27-plex (IL-1β,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,
IL-12(p70), IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF,
GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PGDF-
BB, RANTES, TNF-α and VEGF) and the Bio-Plex Pro
TGF-β Panel 3-plex (TGF-β 1, 2 and 3) assays (Bio-Rad
Laboratories, CA). Acquisition was performed on the Bio
Plex 200 platform (Bio Rad Laboratories).
Statistical analysis
Statistical analysis was carried out in Statistica version
12 (StatSoft, OK) and GraphPad Prism version 5 software
(GraphPad Software, CA). Normality of data was tested
using the D’Agostino-Pearson omnibus test. Non-parametric
data was described using medians and interquartile ranges.
Differences between groups were compared using the
Mann-Whitney test where there were only two groups or
the Kruskal-Wallis test in cases of three or more groups.
Multiple comparisons were preformed using the Dunn’s
post-test where the Kruskal-Wallis p value was significant.
Data with normal distribution was described using means
and 95% confidence intervals (95% CI). Comparisons
between groups (appearing as rows) were performed
using the unpaired t-test when data was normally distrib-
uted. Categorical data was described using proportions and
95% CI and the differences in observed frequencies across
groups were analysed using the χ2 test (or Fisher’s test
when the number in a cell was low). Correlational analysis
was performed using the Spearman rank correlation test.
All hypothesis testing was done at 95% confidence intervals
and results were regarded as significant if p < 0.05.
Results
Demographics
We recruited 169 patients into the study. The distribution
of the patients was 46 HBV/HIV co-infected; 47 HBV
mono-infected; 39 HIV mono-infected and; 37 HBV/HIV
uninfected controls attending the gastroenterology clinic
(Table 1).
Immunological and virological characteristics
All co-infected and HIV mono-infected patients were on
antiretroviraltherapy for ≥3 months (Table 1). All HIV-
infected patients (HBV/HIV co-infected and HIV mono-
infected) were on tenofovir together with emtricitabine or
lamivudine. HIV virological suppression was achieved
by 30/36 (78%) of co-infected compared to 27/33
(82%) of HIV mono-infected patients (Table 1). Only
12/47 (25%) of HBV mono-infected patients were on
antiviral therapy while the duration of therapy varied
from one week to 24 months. Of the 12 HBV patients
receiving antiviral therapy, 11 were on tenofovir while
a single patient was on lamivudine. The median CD4
cell count in the co-infected group was 328 cells/μl, IQR
242–562 compared to 528 cells/μl; IQR 367–657 in the
HIV mono-infected group, p = 0.04. HBV viral loads had
significant negative correlation with duration of therapy
among co-infected patients, rho = − 0.48; p < 0.05.
Prevalence of liver fibrosis using non-invasive markers
Due to the low number of HBV-mono-infected pa-
tients on therapy, statistical analysis was done taking
the treated and untreated HBV mono-infected pa-
tients as a single group. The median of TE in the
treated HBV mono-infected group was 7.2 kPa (IQR:
5.3–13.0) compared to 7.3 (IQR: 5.7–8.8) in the un-
treated HBV mono-infected, p = 0.98. Taken as a sin-
gle group, the HBV mono-infected group had the
highest proportion 7/38 (18%) of patients with TE
values ≥13 kPa compared to 4/36 (11%) in the co-
infected group and 3/32 (9%) in the HIV mono-
infected group. (Table 2). The proportion of patients
with TE values between 7 and 13 kPa was comparable
between the co-infected and HBV-mono-infected
groups at 11/36 (31%) and 12/38 (32%), respectively.
These proportions were higher than the 1/32 (3%) and
6/29 (21%) among HIV-monoinfected and controls,
respectively.
Microbial translocation markers
The HBV/HIV group had median serum sCD14 concen-
tration of 3.6 μg/ml; IQR 2.4–6.2 compared to 1.8 μg/
ml; IQR 1.1–2.4 in the HBV group, 2.4 μg/ml; IQR 1.8–
4.3 in the HIV group and 1.6 μg/ml; IQR 1.2–2.2 in the
control group, p < 0.0001. Statistically significant differ-
ences in serum concentration were observed between
co-infected compared to the HBV mono-infected (p < 0.
0001); co-infected against the controls (p < 0.00001), HBV
mono-infected versus HIV mono-infected (p = 0.02) and
controls compared to HIV mono-infected (p = 0.0007)
(Fig. 1). Serum LBP concentrations showed a trend to-
ward increased levels in the co-infected group com-
pared to the other groups, p = 0.06 (Additional file 1:
Table S1). There were no statistically significant differ-
ences in the serum concentration of microbial
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translocation markers between the treated and un-
treated HBV mono-infected patients (data not shown).
Expression of CD38, HLA-DR, PD-1 and CTLA-4 on CD4+
and CD8+ T lymphocytes
There were no significant differences in the expres-
sion of cell-associated immune markers between the
treated and untreated HBV mono-infected groups and
as a result were considered as a single group for stat-
istical analysis. The median percentage CD8+/CD38
+/HLA-DR+ co-expression in HBV/HIV co-infected
patients was 30%; IQR 17–53 compared to 23%; IQR
16–33 in the HIV mono-infected group, 17%; IQR
14–22 in the HBV mono-infected and 16%; IQR 8–26
in the control group (p < 0.0001) (Table 3). The ex-
pression of PD-1 on both CD4+ and CD8+ T lympho-
cytes was also highest amongst co-infected patients
compared to all other groups, p < 0.0001 in each instance.
Post-test analysis showed that %CD8+/PD-1 was signifi-
cantly higher among co-infected patients compared to
HBV mono-infected and controls. Percentage CD4+/PD-1+
was significantly higher in the co-infected group (median
22; IQR 15–33) and HIV mono-infected (22; IQR 15–26)
compared to HBV mono-infected (13.2; IQR 11–20) and
controls (15; IQR 9–21). The HIV mono-infected group
had higher %CD4+/PD-1+ compared to the control group
(Table 3).
Detection of serum cytokines
Within the HBV mono-infected group, only PDGF
was statistically significantly different in concentration be-
tween the treated and untreated patients with the
treated having median 3.84 ng/ml (IQR: 3.28–4.78)
compared to 2.97 ng/ml (IQR: 1.81–3.57) among un-
treated patients, p = 0.04. We therefore considered the
treated and untreated HBV mono-infected patients as a
single group for multigroup comparison. Levels of basic
fibroblast growth factor, IL-9 and IL-17 were particularly
elevated in the HBV mono-infected group (Table 4).
Serum levels of IP-10 were high among co-infected pa-
tients. TGF-beta isotypes were highly expressed in the
HIV-mono-infected group. Analysis of serum cytokine
concentrations was also performed excluding the con-
trol group significance levels (shown as p2 in Table 4).










Age in years (mean ± standard deviation) 38.5 ± 8.2 37.9 ± 12.3 37.9 ± 9.7 43.8 ± 11.4 0.04
Males (%) 22 (47%) 22 (47%) 16 (39%) 25 (41%) 0.1
Ethnicity, n (%)
African 31 (67%) 18 (38%) 17 (44%) 5(14%)
Mixed 14 (32%) 25 (53%) 22 (56%) 30 (81%) 0.0001b
Caucasian 1 (1%) 3 (7%) – 2 (5%)
Asian – 1 (2%) – –
Body mass index 24.3 ± 5.1 28.0 ± 9.0 24.6 ± 3.5 27.0 ± 5.9 0.2
Alcohol consumption 8/46 (17%) 9/47 (19%) 11/39 (28%) 14/37 (38%) 0.1
Herbal medicine use (current/past) 1/46 (2%) 5/47 (11%) 1/39 (3%) 5/37 (14%) 0.11
ART, months
Median (IQR)














0.5 (0.3–0.7) 1.5 (1.1–2.1) 0.7 (0.6–1.0) 1.6 (1.3–2.1) < 0.0001
CD4 nadir 256 (144–369) 281 (169–440) 0.2
Detectable plasma HIV-1 viral load 10/36 (27.8%) n/a 6/33 (18.1%) n/a 0.4
HIV-1 viral load > 1000 copies/mla 6/36 (17%) n/a 3/33 (9.1%) n/a 0.5
Detectable plasma HBV DNA 22/45 (49%) 32/44 (73%) n/a n/a 0.03
Plasma HBV DNA > 2000 IU/mlc 12/45 (26%) 15/44 (32%) n/a n/a 0.5
HBeAg positive, (%) 13/46 (28%) 6/46 (13%) n/a n/a 0.1
a1000 copies/ml chosen for HIV-1 viral load as this defines virological failure in patients on ART
bIndicates where a chi test was used for statistical analysis
cHBV DNA > 2000 IU/ml cut-off used as it may indicate the need for therapy in some patients
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Correlation was analysed for all study participants as a
single group as well as according to their infection sta-
tus using all continuous variables measured in the
study. There were significant positive correlations be-
tween IP-10 and sCD14 (rho = 0.32; p = 0.00008) and
IP-10 with LBP (rho = 0.19; p = 0.02). IP-10 was also
positively correlated with HIV viral load (rho = 0.42; p
= 0.004) and HBV viral load (rho = 0.37, p = 0.02) in
the co-infected group. Principle component analysis of
serum cytokine concentrations showed relatively good
distinction between HBV mono-infected, HBV/HIV co-
infected patients from the HIV mono-infected and con-
trols. There was poor distinction between the HIV
mono-infected participants and controls (Fig. 2).
Correlation of viral and immune markers with non-
invasive tests of liver fibrosis
Correlation was performed for all participants without
stratification of groups and according to the individ-
ual groups. In the ungrouped analyses, median stiff-
ness had significant positive correlation with HIV
viral load (rho = 0.29, p = 0.02) and HBV viral load
(rho = 0.30, p = 0.007). In addition, HBV viral load was
significantly correlated with APRI score within the
HBV mono-infected group (rho = 0.5, p = 0.003). Sol-
uble CD14 positively correlated with %CD8+/CD38
Fig. 1 Plasma sCD14 according to group. The middle lines show the
median while the boxes represent the 25th and 75th percentiles. The
whiskers show the non-outlier range, asterix represent the outliers and
the solid black squares indicate the extreme values. The y axis showing
the sCD14 values is drawn using a logarithmic scale. The medians and
interquartile ranges in parenthesis were as follows: Co-infected 3.6 μg/ml
(IQR, 2.4–6.2); HBV mono-infected 1.8 μg/ml (1.1–2.4); HIV mono-infected
2.4 μg/ml (1.8–4.3) and control 1.6 (1.2–2.2)
Table 2 Summary and distribution of fibrosis results according to group
HBV/HIV HBV HIV Controls p
Valid Fibroscan 36/40 (90%) 38/41 (93%) 32/37 (86%) 29/30 (97%) 0.5
Fibroscan (kPa) n = 36 n = 38 n = 32 n = 29
< 7.0 21 (58%) 19 (50%) 28 (88%) 23 (79%)
7.0–13 11 (31%) 12 (32%) 1 (3%) 6 (21%) 0.002b
≥13 4 (11%) 7 (18%) 3 (9%) –
APRI n = 43 n = 35 n = 26 n = 22
< 0.5 31 (72%) 25 (71%) 21 (81%) 19 (86%)
0.5–1.5 9 (21%) 7 (20%) 4 (15%) 3 (14%) 0.8b
> 1.5 3 (7%) 3 (9%) 1 (4%) –
FIB-4 n = 42 n = 34 n = 26 n = 22
< 1.30 31 (74%) 27 (79%) 19 (73%) 20 (91%)
1.30–3.25 9 (21%) 4 (12%) 7 (27%) 2 (9%) 0.32b
> 3.25 2 (5%) 3 (9%) – –
ALT, U/La 34 (24–45) 25 (22–47) 31 (21–44) 24 (19–39) 0.3
AST, U/La 31 (25–46) 27 (23–42) 32 (27–45) 21 (18–32) 0.001
Fibroscan, kPaa 6.2 (4.8–8.0) 6.9 (5.5–8.8) 4.7 (3.9–5.9) 5.6 (4.6–6.8) 0.001
APRIa 0.32 (0.24–0.58) 0.34 (0.21–0.66) 0.32 (0.23–0.46) 0.21 (0.13–0.42) 0.08
FIB-4a 0.96 (0.58–1.30) 0.86 (0.59–1.20) 0.77 (0.55–1.30) 0.63 (0.41–1.00) 0.1
aMedian values and IQRs are shown in parenthesis
bIndicates where a chi test was used
The data in bold are entries where there were zero observations for the particular cell
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+/HLA-DR+ (rho = 0.19, p = 0.01) and also percentage
CD8+/PD-1+ expression (rho = 0.2, p = 0.009). Soluble
CD14 showed significant negative correlation to CD4
+ T cell count (rho = − 0.04, p < 0.0001) and CD4/CD8
ratio (rho = − 0.5, p < 0.00001) (Additional file 1: Table
S3). HIV viral loads positively correlated with CD8
+/CD38+/HLA-DR+ expression within the co-infected
group (rho = 0.4, p < 0.05) but not in the HIV mono-
infected (Additional file 1: Figure S2). We did not ob-
serve any statistically significant correlations between
Table 3 Expression of cell-surface expressed markers on CD4+ and CD8+ T lymphocytes
Co-infected HBV Mono HIV Mono Control p
%CD4/CD38+/HLA-DR+ 9.9 (6.2–17) 4.7 (3.6–6.3) 7 (4.5–12) 3.5 (2.6–6) < 0.0001
%CD8/CD38+/HLA-DR+ 30 (17–53) 17 (14–22) 23 (16–33) 16 (7.7–26) < 0.0001
%CD4+/PD-1+ 25 (18–34) 18 (13–23) 21 (15–27) 13 (8–22) < 0.0001
%CD8+/PD-1+ 22 (15–33) 13.2 (11–20) 22 (15–26) 15 (9–21) < 0.0001
Median and IQR (in parenthesis) are shown. Values are percentages of either CD4+ or CD8+ T cells expressing marker of interest
Table 4 Median plasma cytokine concentrations
Units LDL HBV/HIV, n = 45 HBV, n = 44 HIV, n = 39 Control, n = 19 p p2
IL-1β pg/ml 0.47 1.3 (0.9–2.8) 2 (1.5–3.1) 1.2 (0.9–1.9) 1.7 (1.2–2.8) 0.001 0.0004
IL-1ra pg/ml 5.33 59 (40.4–100.8) 110.8 (85.1–376.7) 62.2 (40.4–85.8) 69.8 (53.7–106.3) < 0.00001 < 0.00001
IL-2 pg/ml 1.52 0 (0–5.4) 8 (0.5–18.4) 0 (0–7.3) 0 (0–4.7) 0.0002 0.0002
IL-4 pg/ml 0.24 2.2 (1.6–3) 2.8 (2.1–4.1) 2.2 (1.6–3.2) 2.3 (2–2.9) 0.03 0.02
IL-5a pg/ml 1.00 0 (0–7) 0 (0–15.5) 0 (0–0) 0 (0–4) n/a n/a
IL-6 pg/ml 1.68 10 (0.8–18.3) 11.3 (7.2–29.3) 4.3 (0.5–10.3) 6.3 (1.5–12.5) 0.002 0.005
IL-7 pg/ml 0.84 9 (3.7–14.6) 7.4 (2.5–14.8) 1.2 (0–7.9) 5.9 (1.2–9) 0.002 0.001
IL-8 pg/ml 2.44 26.8 (19.5–53.3) 51.9 (22.8–121.8) 21.7 (13.9–43.6) 120.1 (35.2–437.2) < 0.00001 0.002
IL-9 pg/ml 1.19 54.7 (44.5–73.8) 73.1 (55.6–118.5) 59.5 (45.5–83.7) 78.2 (57.6–97.1) 0.01 0.02
IL-10 pg/ml 2.21 10.2 (5.8–18.8) 15.9 (11.3–29.2) 9.5 (5.6–14.5) 9.7 (7.7–15.9) 0.001 0.005
IL-12 pg/ml 2.25 50.8 (31.9–63.6) 47.4 (27.1–87.9) 35.2 (19.4–59.9) 44.5 (31.7–65.4) 0.3 0.2
IL-13 pg/ml 0.40 12 (6.2–24.8) 13.8 (8–29.6) 9.5 (5.2–13.7) 6.5 (4.8–10.4) 0.004 0.02
IL-15a pg/ml 5.73 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n/a
IL-17 pg/ml 5.81 44.5 (27.7–84.3) 81.7 (61.6–133.2) 67.7 (54.1–111.9) 78.5 (64.1–110.4) 0.004 0.006
EOTAXIN pg/ml 1.75 107.9 (81.2–172.8) 129.3 (72.1–171.3) 115.8 (73.9–160.1) 142.5 (93.1–261.1) 0.4 0.8
Basic-FGF pg/ml 3.91 43.1 (21.8–66.9) 65.7 (46.2–92.3) 44.8 (24.2–61.3) 50.4 (34.2–65.7) 0.0006 0.0002
G-CSF pg/ml 3.06 51.1 (32.1–66.1) 59.7 (44.1–98.6) 41.9 (30.3–58.1) 37.6 (32.1–66.1) 0.006 0.004
GM-CSF pg/ml 2.9 0 (0–22.2) 25.5 (0–87.6) 0 (0–35.7) 0.6 (0–15.3) 0.006 0.003
IFN-γ pg/ml 42.9 88.7 (57.5–145.3) 121.2 (80.1–182.0) 66.7 (48–125.7) 97.2 (51.1–116.7) 0.004 0.004
IP-10 ng/ml 4.94 1.5 (1.0–2.8) 0.9 (0.7–1.5) 1.1 (0.8–1.5) 1 (0.8–1.2) 0.0001 0.0001
MCP-1 pg/ml 1.24 4.7 (0–27.2) 21.3 (0–54.4) 0.4 (0–20.5) 17.3 (0–78.8) 0.03 0.2
MIP-1a pg/ml 0.15 4.4 (1.3–7.7) 7.3 (4.6–11.4) 4.7 (2.5–6.3) 8.2 (5.3–10.3) 0.001 0.006
PDGF ng/ml 1.00 2.4 (1.7–3.3) 3.2 (1.8–3.9) 2.9 (1.9–3.8) 3.3 (2.3–4.5) 0.09 0.2
MIP-1b pg/ml 0.46 140.9 (95.5–218.8) 147.3 (102.7–199.1) 128.8 (103.8–227.4) 217 (155.5–264.7) 0.06 0.9
RANTES ng/ml 3.72 19.9 (16.7–26.7) 19.0 (13.8–23.1) 19.1 (16.7–22.6) 22.1 (17.8–24.7) 0.2 0.3
TNF-a pg/ml 3.77 19.5 (15.1–27.4) 23.5 (18.5–54.5) 19.5 (15–24) 18.5 (15.1–26.2) 0.01 0.007
VEGF pg/ml 2.30 88.9 (52.2–147.7) 117.7 (60–211.5) 77.8 (45.2–138) 89.6 (51.5–160.5) 0.2 0.09
TGF-β1 ng/ml 41.7 (34.1–53.6) 46.4 (38.3–56.8) 49.7 (42.1–55.7) 48.2 (42.5–55) 0.10 0.06
TGF-β2 ng/ml 1.8 (1.7–1.9) 2.1 (1.8–2.4) 2.3 (1.8–2.5) 2 (1.7–2.4) < 0.00001 < 0.00001
TGF-β3 ng/ml 1.3(1.2–1.5) 1.9 (1.4–2.2) 2.2 (1.5–2.3) 1.8 (1.4–2.2) < 0.00001 < 0.00001
aPlasma levels of IL-5 and IL-15 were below detection limit in most samples across the groups hence the medians of 0 pg/ml. Column heading p2 shows the level
of significance of Kruskal-Wallis test excluding the control group
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cytokine levels and liver stiffness except for IL-5 (rho = 0.
17, p = 0.049), TGF-β2 (rho = − 0.26, p = 0.003), TGF-β2
(rho = − 0.31, p < 0.001) and TGF-β3 (rho = − 0.31, p
< 0.001) (Additional file 1: Table S3).
Molecular characterization of HBV and association with
liver fibrosis
Of 22 viraemic co-infected patients, 13 (59.1%) were
successfully sequenced compared to 29/32 (90.6%) of HBV
mono-infected participants (Additional file 1: Figure S3).
The medians of the TE scores for the different genotypes
were 7.9 kPa; IQR 5.8–12.1 for genotype A (n = 21),
6.3 kPa; IQR 5.8–7.6 for genotype D (n = 11) and 7.0 kPa;
IQR 5.3–7.9 for genotype E (n = 4). There was no statisti-
cally significant difference in TE scores according to the
HBV genotype, p = 0.43 (Additional file 1: Table S2). No
classic mutations associated with resistance to nucleotide
reverse transcriptase inhibitors were observed in the co-
infected or HBV mono-infected group.
Discussion
HIV co-infection has an adverse impact on the natural
progression of hepatitis B [16]. On the contrary, data
describing the effect of hepatitis B on HIV infection is
limited. Despite being on ART, co-infected patients had
lower CD4 cell counts compared to those infected with
HIV alone. The proportion of patients with plasma HIV
viral load > 1000 copies/ml was also higher among those
with co-infection (17%) compared to those with HIV
alone (9%) as shown in Table 2. This may also explain
the low CD4 cell counts among co-infected patients as
negative correlation was observed between HIV viral
load and CD4 cell counts. We did not have the data on the
CD4 counts before these patients were started on ART but
other studies have shown that HBV/HIV co-infected indi-
viduals have lower CD4 counts or impaired CD4 cell count
recovery compared to those with resolved HBV infection
and HBV-uninfected patients independent of duration of
ART [4, 17–19]. Data on nadir CD4 counts in this study
showed no statistically significant differences between the
co-infected and HIV mono-infected groups. Reasons for
the decreased immune recovery include upregulation of
apoptotic pathways in co-infection and sequestration of
lymphocytes within the spleen following HBV-driven liver
fibrosis [19, 20]. Low CD4/CD8 ratios despite effective
ART are associated with continuous immune dysregulation,
immune senescence and are predictive of non-AIDS
morbidity and mortality [21]. Our results show co-infected
patients with significantly lower median CD4/CD8 ratio
compared to those infected with HIV alone which is
explained by the fact that normalisation of CD4/CD8 ratio
is solely based on the recovery of CD4 cells.
HBV mono-infected patients more frequently had
detectable HBV DNA compared to the co-infected
patients; (49% vs 73%, p = 0.03). This is expected as not all
the HBV mono-infected patients were on therapy. The
Fig. 2 Principle component analysis of plasma concentrations of microbial translocation markers and cytokines. The plot shoes serum cytokine
signatures of the four patients groups. The prediction ellipses represent 0.95 probability that a new observation from the same group will fall
inside area. The ellipses for the co-infected and HBV groups appear to be distinct from those of the HIV mono-infected and control groups. The x
and y-axis show principal component 1 and principal component 2 that explain 44.3% and 10.1% of the total variance observed, respectively
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presence of HBV DNA among the co-infected patients
who were on effective therapy may indicate non-adherence
to therapy. Another reason may be that HBV DNA load
on therapy is a function of time because of the significant
negative correlation observed between time on therapy
and HBV viraemia. A study of Zambian and South African
patients reported that only 15/21 (71%) of co-infected
patients achieved HBV suppression after a year of tenofovir
plus lamivudine or emtricitabine [22]. However, not all
HBV-infected patients on therapy will achieve virologic
suppression even without obvious drug-resistance muta-
tions, especially those with high levels of replication such
as in HIV co-infection and those that are HBeAg positive
have delayed viral suppression [23–25]. The higher preva-
lence of HBeAg among co-infected patients compared to
HBV mono-infected patients is a well-recognised effect of
HIV infection [16, 26–28]. Even with administration of an
effective regimen such as tenofovir plus emtricitabine, not
all patients will achieve HBeAg seroconversion. A previous
study reported that after 5 years of continuous therapy
HBeAg seroconversion was achieved by only 57% of HIV/
HBV co-infected patients [29].
Our results of TE showed that the HBV mono-infected
group had the highest proportion of patients with signifi-
cant or advanced fibrosis and the highest the median of TE
value compared to all other groups. The results showing a
higher proportion of patients with significant fibrosis
among those with HBV/HIV coinfection compared to HIV
mono-infected patients are consistent with findings from
other groups where coinfection was associated with higher
TE values [30–32]. HIV alone independently increases liver
fibrosis progression rates [33, 34]. However, the finding of a
higher proportion of HBV mono-infected individuals with
advanced fibrosis compared to HIV mono-infected is not
unexpected because the majority of HBV mono-infected
patients in this cohort were not on treatment. Treatment
of hepatitis B improves liver fibrosis and this probably
explains the reason for lower TE values in the co-infected
patients compared to those with HBV mono-infection [35].
Soluble CD14 is a marker of monocyte/macrophage
activation that is normally induced by exposure to LPS. The
results from this study showed that co-infected patients had
the highest plasma sCD14 levels compared to those infected
with either HBV or HIV alone. Research in paediatric and
adult patients infected with HIV has shown that despite
ART, there is persistently higher immune activation punctu-
ated by elevated levels of sCD14 and that this is not related
to HIV viraemia [36, 37]. Our results also support these
findings because plasma sCD14 did not correlate with either
plasma HBV DNA or HIV RNA, thus supporting the
idea that gut microbial translocation is independent of
on-treatment viral load. This may explain why no difference
was detected in microbial translocation markers between
HBV mono-infected patients that were on therapy and
those that were not. A potential mechanism for continued
monocyte activation may be due to blunted recovery of
CD4 T cells during ART [38]. However, this study cannot
determine the rate of CD4 T cell recovery of the HIV-
infected patients that were recruited because of its cross-
sectional design. ART does not restore gut integrity and
therefore continued elevations of LBP and sCD14 are
expected [39, 40]. The overall finding from the microbial
translocation markers and liver fibrosis markers would
seem to suggest that gut translocation is not associated with
liver stiffness in this treated cohort. Instead, according to
the results of the ungrouped analysis viral replication is the
driver of liver fibrosis.
Co-infected patients displayed the highest percentage of
CD4+ and CD8+ T lymphocytes co-expressing HLA-DR
and CD38 compared to other groups in this study. The
results suggest that HIV infection is the driver of immune
activation because of the positive correlation between HIV
viraemia and CD8/CD38/HLA-DR expression. Significant
positive correlation was observed in the ungrouped ana-
lysis and the co-infected group. Interestingly, there was no
correlation between the expression of peripheral blood
cell-based immune markers of activation and liver stiffness
as measured by any of the fibrosis markers. This may be
due to the fact that the study measured immune activation
in peripheral blood and not the hepatic environment.
Research on the hepatic environment in HBV/HIV co-
infected patients previously found no evidence of increased
inflammation but rather apoptosis as the driver of liver
fibrosis [41]. The elevated serum concentrations of
IL-9, IL-17 and fibrogenic basic fibroblast growth factor in
plasma of HBV mono-infected patients support recent
reports highlighting the roles of these biomarkers in
pathogenesis of liver fibrosis due to viral hepatitis [42–45].
The co-infected group had significantly higher levels of
IP-10 compared to the HBV mono-infected group. In-
creased IP-10 levels could be an indicator of continued
immune activation from viral replication and gut trans-
location in HBV/HIV co-infection and have been described
as remaining elevated in co-infected patients despite
combination antiretroviral therapy [46].
Our study hypothesis was that in co-infection with
HIV and HBV, HIV facilitates the development of liver
fibrosis via immune activation in response to the leakage
of gut microbial products into the systemic circulation.
Instead, we found that although there was increased micro-
bial translocation shown by increased sCD14 and elevated
immune dysregulation in HBV/HIV co-infected patients,
the proportion of patients with moderate/advanced liver
fibrosis as determined by TE was higher in the HBV
mono-infected group compared to those with co-infection.
The finding of no significant correlation between microbial
translocation markers and liver fibrosis scores would seem
to imply that microbial products are not the driver of
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fibrosis but rather viral replication. This is because TE had
significant positive correlation with both HIV and HBV
viraemia in the ungrouped analysis. The relationship of
active viral replication with fibrosis implicates active
antigen-specific anti-viral responses as being important
to pathogenesis of liver fibrosis. Viral replication as the
driver of liver fibrosis has been reported among treatment-
naïve HBV/HIV co-infected patients in Zambia and
Switzerland [47].
There are some limitations in this study. The sample size
of treated and untreated HBV mono-infected patients was
too small to consider them as separate groups, which would
have been ideal. The small number of HBV mono-infected
patients on therapy is a reflection of the lack of prioritization
of therapy for HBV infections in South Africa. The non-
availability of liver biopsies from study participants makes it
difficult to validate the accuracy of the results of the non-
invasive tests for fibrosis although the use of Fibroscan has
been validated in numerous studies in the past [48, 49].
Valid TE measurements were not obtained on all patients
due to visceral obesity and unavailability of a large probe.
An effect of other undiagnosed infections on expression
of markers of immune activation cannot be eliminated
although any patients with overt symptoms of other
infectious diseases were excluded. Another limitation is
that the assessment of immune markers was not virus-
specific. This study did not measure microbial compo-
nents such as LPS or microbial 16S rRNA per se but rather
products of the host physiologic response to microbial
translocation. We measured LBP and sCD14 in this current
study because LPS has a short half-life in circulation and
its measurement using the widely utilized Limulus assay is
subject to interference from other molecules in the blood
where it may be bound to serum binding proteins [50].
Other studies have shown strong correlation between LPS
levels and sCD14 and/or LBP [50, 51]. The effect of previ-
ously described single nucleotide polymorphisms of the
CD14 gene on the expression of sCD14 was not explored
in this study but variations in the gene could potentially
influence the long-term recovery of CD4 T cells in HIV-
infected patients on HAART [52]. Nevertheless, the data
from this study is important to the process of developing
prospective studies to monitor prognosis of HBV infection,
especially among HBV-mono-infected patients who are
under-diagnosed and under-treated.
Conclusions
The findings suggest that HBV-mono-infected patients
in this study have worse liver fibrosis than patients with
HBV/HIV co-infection despite immune activation being
higher in the latter group. HBV/HIV co-infected patients in
South Africa have better access to screening, effective treat-
ment and monitoring than those that are HBV-mono-
infected. There is a need for screening for HBV infection
and monitoring of HBV mono-infected patients to allow
initiation of timely and effective interventions in order
to prevent the development of complications such as
advanced liver fibrosis and/or hepatocellular carcinoma.
Additional file
Additional file 1: Table S1. Serum LPB concentration according to
patient group (μg/ml). Table S2. Proportions of fibrosis scores according
to the HBV genotype. Table S3. Multiple correlation analysis of all
patients ungrouped. Statistically significant correlations appear in red
font. Figure S1. Gating strategy for Immune Activation panel. Plot A
shows the singlet population gating while Plot B represents the SSC
against FSC plot indicating the position of the singlet cells of the
lymphocyte population. Plot C shows the lymphocyte population as
shown by less complexity (SS) and intense staining for CD45-KO in a plot
of side scatter against CD45-KO. Plot D shows the CD3+ population (Gate G)
as gated from Gate F shown in Plot C. Using colour precedence and back
gating, Plot D also shows the non-lymphocyte population (red colour) that is
included within gate F based on use of complexity (SS INT) and staining for
CD45. Picture E shows the CD4+ in the blue colour (gate H) and the CD8+
lymphocytes in the magenta colour (gate I). Plot F shows the CD8+
population staining for CD38-PE and HLA-DR-APC gated from gate I.
The gate placement was based on defined fluorescence minus one
(FMO) settings. Figure S2. Scatter plot of % CD8/CD38+/HLA-DR+ in
the co-infected group. The plot only includes HBV/HIV co-infected
patients. All patients with undetectable HIV viral load are assigned
values of zero and appear on the y-axis as dots corresponding with the
percentage expression CD8/CD38+/HLA-DR. Frequency of HBV
genotypes according to HBV and HIV infection status. Among the 13
co-infected patients whose HBV was successfully sequenced, 8 (62%)
were infected with HBV genotype A, 3 (23%) with D and 2 had HBV
genotype E (15%). The distribution of genotypes among the HBV
mono-infected patients was- 16/29 (55%) A, 11/29 (38%) D and 2/29
(7%) E. The red columns represent HBV genotype A, green is for
genotype D and the blue corresponds to genotype E. Genotyping was
frequently more successful in the HBV mono-infected group compared
to the co-infected group. (DOCX 475 kb)
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